Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 2,906

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Mortality Results from a Randomized Prostate-Cancer Screening Trial

Open access
Andriole, Gerald L., Crawford, E. David, Grubb, Robert L., Buys, Saundra S., Chia, David, Church, Timothy R., Fouad, Mona N., Gelmann, Edward P., Kvale, Paul A., Reding, Douglas J., Weissfeld, Joel L., Yokochi, Lance A., O'Brien, Barbara, Clapp, Jonathan D., Rathmell, Joshua M., Riley, Thomas L., Hayes, Richard B., Kramer, Barnett S., Izmirlian, Grant, Miller, Anthony B., Pinsky, Paul F., Prorok, Philip C., Gohagan, John K., Berg, Christine D. · 2009 · New England Journal of Medicine

Abstract

BACKGROUND: The effect of screening with prostate-specific-antigen (PSA) testing and digital rectal examination on the rate of death from prostate cancer is unknown. This is the first report from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial on prostate-cancer mortality. METHODS: From 1993 through 2001, we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects). Men in the screening group were offered annual PSA testing for 6 years and digital rectal examination for 4 years. The subjects and health care providers received the results and decided on the type of follow-up evaluation. Usual care sometimes included screening, as some organizations have recommended. The numbers of all cancers and deaths and causes of death were ascertained. RESULTS: In the screening group, rates of compliance were 85% for PSA testing and 86% for digital rectal examination. Rates of screening in the control group increased from 40% in the first year to 52% in the sixth year for PSA testing and ranged from 41 to 46% for digital rectal examination. After 7 years of follow-up, the incidence of prostate cancer per 10,000 person-years was 116 (2820 cancers) in the screening group and 95 (2322 cancers) in the control group (rate ratio, 1.22; 95% confidence interval [CI], 1.16 to 1.29). The incidence of death per 10,000 person-years was 2.0 (50 deaths) in the screening group and 1.7 (44 deaths) in the control group (rate ratio, 1.13; 95% CI, 0.75 to 1.70). The data at 10 years were 67% complete and consistent with these overall findings. CONCLUSIONS: After 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups. (ClinicalTrials.gov number, NCT00002540.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa0810696

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 5

  1. 10.1001/jama.273.7.548 · doi:10.1001/jama.273.7.548
  2. 2000, Oncology (Williston Park), 14, 267
  3. 10.1111/j.1464-410X.2008.08214.x · doi:10.1111/j.1464-410x.2008.08214.x
  4. 10.1097/01.ju.0000152697.25708.71 · doi:10.1097/01.ju.0000152697.25708.71
  5. 10.1016/S0197-2456(00)00095-7 · doi:10.1016/s0197-2456(00)00095-7

Cited by

See all 2,906

Metadata

Authors
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., Weissfeld, J. L., Yokochi, L. A., O'Brien, B., Clapp, J. D., Rathmell, J. M., Riley, T. L., Hayes, R. B., Kramer, B. S., Izmirlian, G., Miller, A. B., Pinsky, P. F., Prorok, P. C., Gohagan, J. K., & Berg, C. D.
Venue
New England Journal of Medicine
Published
2009-03-26
Volume
360
Issue
13
Pages
1310-1319
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2132528779
Cited by
2,906
References
27
FWCI
314.07
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.